Literature DB >> 19696261

Early CT findings of tomotherapy-induced radiation pneumonitis after treatment of lung malignancy.

Hyun Jin Park1, Ki Jun Kim, Seog Hee Park, Chul-Seung Kay, Jung Suk Oh.   

Abstract

OBJECTIVE: The objective of our study was to evaluate the early CT findings of tomotherapy-induced radiation pneumonitis.
MATERIALS AND METHODS: Tomotherapy was performed during the study period in 31 patients with peripheral pulmonary malignancies, 25 of whom underwent follow-up CT within the first 3 months after tomotherapy. These 25 patients, with a total of 77 target lesions, were enrolled for the analysis. We evaluated pulmonary toxicity by the Common Toxicity Criteria for Adverse Events (CTCAE) method and retrospectively analyzed the CT findings of radiation pneumonitis, focusing on the appearance (attenuation, shape, degree of fibrosis) and location (concentric vs eccentric, centrifugal vs centripetal) of radiation pneumonitis relative to the target lesions.
RESULTS: Radiation pneumonitis developed around 34 target lesions (34/77, 44%) in 13 patients (13/25, 52%) during the first 3 months after tomotherapy. Five patients needed steroid therapy (CTCAE grade 2, 5/25 [20%]) and the remaining eight patients required no additional treatment (CTCAE grade 0 or 1, 20/25 [80%]). In appearance, the common CT findings were irregular shape (18/34), ground-glass attenuation (19/34), and no or minimal fibrosis (33/34). The location of the radiation pneumonitis was eccentric (22/34) and centrifugal (19/34) relative to the target lesions.
CONCLUSION: Radiation pneumonitis commonly developed with minimal clinical findings within 3 months after tomotherapy. The CT findings were nonspecific: focal, irregular-shaped ground-glass opacities with minimal fibrosis. However, the location of the radiation pneumonitis tended not to correspond to the planned target volume and had a centrifugal distribution. In addition, the immediate area around the target tended to be spared.

Entities:  

Mesh:

Year:  2009        PMID: 19696261     DOI: 10.2214/AJR.08.2298

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  6 in total

1.  Detection and early phase assessment of radiation-induced lung injury in mice using micro-CT.

Authors:  Shigeyoshi Saito; Kenya Murase
Journal:  PLoS One       Date:  2012-09-24       Impact factor: 3.240

2.  A prospective cohort study on postoperative radiotherapy with TomoDirect using simultaneous integrated boost technique in early breast cancer.

Authors:  Hyo Chun Lee; Sung Hwan Kim; Young Jin Suh; Mi Joo Chung; Dae Gyu Kang; Hyun Joo Choi; Jong Hoon Lee
Journal:  Radiat Oncol       Date:  2014-11-19       Impact factor: 3.481

3.  Evaluation of the Flash effect in breast irradiation using TomoDirect: an investigational study.

Authors:  Dae Gyu Kang; Sung Ill Park; Sung Hwan Kim; Mi Joo Chung; Kwang-Man Lee; Jong Hoon Lee
Journal:  J Radiat Res       Date:  2015-02-10       Impact factor: 2.724

4.  CT patterns and serial CT Changes in lung Cancer patients post stereotactic body radiotherapy (SBRT).

Authors:  Rashid Al-Umairi; Usman Tarique; Rahim Moineddin; Laura Jimenez-Juan; Lan Chau Kha; Patrick Cheung; Anastasia Oikonomou
Journal:  Cancer Imaging       Date:  2022-09-16       Impact factor: 5.605

5.  Hypofractionated radiotherapy for primary or secondary oligometastatic lung cancer using Tomotherapy.

Authors:  Heng-Jui Chang; Hui-Ling Ko; Cheng-Yen Lee; Ren-Hong Wu; Yu-Wung Yeh; Jiunn-Song Jiang; Shang-Jyh Kao; Kwan-Hwa Chi
Journal:  Radiat Oncol       Date:  2012-12-27       Impact factor: 3.481

6.  Assessment and agreement of the CT appearance pattern and its severity grading of radiation-induced lung injury after stereotactic body radiotherapy for lung cancer.

Authors:  Takaya Yamamoto; Noriyuki Kadoya; Yohei Morishita; Yoshinao Sato; Haruo Matsushita; Rei Umezawa; Yojiro Ishikawa; Noriyoshi Takahashi; Yu Katagiri; Ken Takeda; Keiichi Jingu
Journal:  PLoS One       Date:  2018-10-04       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.